Menu
Not yet recruiting NCT06644365

Acupressure Mat on Perceived Stress, Sleep Quality and Premenstrual Symptoms

No phase Interventional Premenstrual Symptoms Effect of Acupressure Mat

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Acupresure mat, Basic mat.
Who it may be relevant to
Registry conditions: Premenstrual Symptoms, Effect of Acupressure Mat. Basic parameters: No limits · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Examining the Effect of Acupressure Mat on Perceived Stress, Sleep Quality and Premenstrual Symptoms in Students Experiencing Premenstrual Syndrome: Randomized Controlled Study

Overview

Purpose of the study: To examine the effect of acupressure mat on perceived stress, sleep quality and premenstrual symptoms in students with premenstrual syndrome. Hypotheses of the study; In the post-test and follow-up test between students who were applied acupressure mat and those who were applied plain mat; H10: There is no difference in terms of severity of premenstrual symptoms. H20: There is no difference in terms of perceived stress. H30: There is no difference in terms of sleep quality.

Interventions

  • Other Acupresure mat
    The Premenstrual Syndrome Scale will be applied and the scale results will be evaluated. Participants who score 132 and above on the scale will be considered to be experiencing PMS. The intervention will be made in the second phase of the study.This practice will continue for three menstrual cycles.
  • Other Basic mat
    The Premenstrual Syndrome Scale will be applied and the scale results will be evaluated. Participants who score 132 and above on the scale will be considered to be experiencing PMS. The intervention will be made in the second phase of the study.Participants in this group will also be sent a reminder message similar to the intervention group. This practice will continue for three menstrual cycles.

Primary outcome measures

  • Premenstrual Syndrome Symptom Scale [Time frame: just before the application starts (pre-test), 12 weeks after the application starts (after the application ends/post-test) and 16 weeks later (follow-up test).]
  • Perceived Stress Scale [Time frame: just before the application starts (pre-test), 12 weeks after the application starts (after the application ends/post-test) and 16 weeks later (follow-up test).]
  • Visual Analog Scale (VAS) Sleep Quality [Time frame: just before the application starts (pre-test), 12 weeks after the application starts (after the application ends/post-test) and 16 weeks later (follow-up test).]

Eligibility criteria

Inclusion criteria

  • Using medication and/or non-medical methods to cope with PMS
  • Having any gynecological disease (abnormal uterine bleeding, myoma, ovarian cyst, etc.)
  • Using contraceptive medication.

Exclusion criteria

  • Participants wanting to withdraw from the study at any stage of the study
  • Participants not complying with the research plan
  • Diagnosed with a psychiatric or gynecological disease during the study
  • Participants starting to receive additional treatment for PMS during the study period

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Supportive care

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06644365 · 2024

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗